title: Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC).
abstract: We report outcomes on 23 patients with oligometastastic (1 or 2 sites) NSCLC treated with aggressive local, regional, and systemic treatment. The results suggest that this is a favorable subset of patients who may benefit from such an approach, with a 22% rate of long-term survival. This treatment strategy is a departure from the usual practice of palliative-only therapy for all NSCLC patients presenting with metastatic disease.
authors.affiliation: Department of Radiation Oncology, Section of Medical Oncology, Rush University Medical Center, Chicago, IL 60612, USA.
authors.forename: Atif J
authors.initials: AJ
authors.lastname: Khan
authors.forename: Par S
authors.initials: PS
authors.lastname: Mehta
authors.forename: Thomas W
authors.initials: TW
authors.lastname: Zusag
authors.forename: Philip D
authors.initials: PD
authors.lastname: Bonomi
authors.forename: L
authors.initials: L
authors.lastname: Penfield Faber
authors.forename: Susan
authors.initials: S
authors.lastname: Shott
authors.forename: Ross A
authors.initials: RA
authors.lastname: Abrams
mesh_terms: D000328:Adult; D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000401:mortality / Q000556:secondary / Q000628:therapy*; D003131:Combined Modality Therapy / Q000379:methods*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D016896:Treatment Outcome